Skip to content

Chemo- and Radiotherapy in Epithelial Vulvar Cancer

Chemo- and Radiotherapy in Epithelial Vulvar Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01304667
Acronym
CARE
Enrollment
1618
Registered
2011-02-25
Start date
2011-02-28
Completion date
2012-06-30
Last updated
2016-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radio/Chemotherapy in Node Positive Advanced Vulvar Cancer

Keywords

Vulvar cancer, Radiotherapy, Chemotherapy

Brief summary

This retrospective, multicenter study is designed to collect tumor characteristics as well as treatment data from patients diagnosed with primary or recurrent squamous cell cancer of the vulva with emphasis on indication and application of radio- and chemotherapy. Application of chemotherapy in primary treatment of vulvar cancer is rare; the study collective is therefore extended to relapsed disease.

Detailed description

All patients with primary squamous cell cancer of the vulva \> stage Ia who were diagnosed and received treatment between 1998 and 2008 at the participating centres will be included in the study. Furthermore patients with recurrent disease diagnosed and treated at the participating centres during the same time period can be included given that they not only underwent surgical excision for treatment. For centers with restricted resources for data entry an alternative study collective was defined: All Patients with primary or relapsed squamous cell vulvar cancer receiving radio- and/or chemotherapy for treatment at the participating centres between 1998 and 2008 will be included in the study. This also includes node negative patients receiving radio/chemotherapy for other reasons. The participating centers themselves have to decide which study collective they are documenting, dependent on their available resources.

Interventions

None listed

Sponsors

medac GmbH
CollaboratorINDUSTRY
Philipps University Marburg
CollaboratorOTHER
AGO Study Group
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients with primary squamous cell vulvar cancer except stage Ia disease regardless of the received treatment 2. Patients with recurrent squamous cell vulvar cancer, if the relapse was not only treated with a surgical excision. 3. Or alternatively, dependent on the decision of the participating center: -Patients with primary or relapsed squamous cell vulvar cancer receiving radio- and/or chemotherapy for treatment regardless of nodal involvement. 4. Patients who were diagnosed with and treated for primary or relapsed vulvar cancer between 1998 and 2008 5. Women aged ≥ 18 years

Exclusion criteria

1. Patients with benign or precursor lesions (VIN - vulvar intraepithelial neoplasia) of the vulva 2. Patients with non-squamous neoplasia of the vulva (e.g. melanoma) 3. Patients with verrucous vulvar cancer 4. Patients with relapsed squamous cell vulvar cancer only receiving surgical excision for treatment. 5. Patients with secondary cancers if those interfered with the treatment of vulvar disease

Design outcomes

Primary

MeasureTime frameDescription
Determination of several specific characteristicsData from vulvar cancer pts between 1998 and 2008 will be included in the study. This also includes node negative patients receiving radi* Determination of the fraction of node positive patients to estimate the number of participating centers and sample size for a subsequent prospective trial. * Determination of the prognostic impact of the number of positive lymph nodes and the stage of disease to define indication criteria for adjuvant radio/chemotherapy for a subsequent prospective trial. * Identification of indication criteria for adjuvant/therapeutic/palliative radio/chemotherapy

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026